The verdict
You do not need a separate anti-dementia diet, an anti-cancer diet, and an anti-heart-disease regimen. A short list of shared modifiable levers — staying physically active, keeping blood pressure, LDL, blood sugar and body fat down, not smoking, going easy on alcohol — lowers the risk of several leading age-related diseases at once. That overlap is why these levers rank first: pull one, and several outcomes move together.
Two honest bounds keep that verdict from over-promising. First, most of the per-disease effects behind it are modest and observational — estimated across populations, not measured in any one person. And the levers do not transfer uniformly from disease to disease. Parkinson’s barely follows the pattern, and a lever that helps one eye disease does nothing clear for its neighbour.
Second, put the question to its sharpest test — does pulling a lever actually prevent a disease, not just move a risk marker? The answer favours a single well-understood lever over a purpose-built regimen. That test has been run most directly on dementia, which now has its own cut. Lowering blood pressure prevents incident dementia in randomized trials — a small but real absolute effect, bought on a pill already prescribed for the heart. A dedicated bundle of diet, exercise and cognitive training aimed at the brain has not cleared the same bar -> Dementia Prevention. The lesson generalizes across the outcome menu. The diet-detail levers that draw the most attention work, where they work at all, through the same cardiometabolic pathways as the shared core — they reinforce those levers, they do not add new ones alongside them.
Start with why the same short list keeps reappearing.
One set of levers, several diseases
Line up the modifiable-risk-factor lists the wiki holds for four leading age-related outcomes — dementia, cardiovascular disease, cancer, Parkinson’s disease. A small set of exposures recurs across most of them, in the same direction: excess body fat, physical inactivity, diabetes and high blood sugar, high blood pressure, high LDL, smoking, and heavy alcohol use. No single disease body states this; each was written for its own outcome. The recurrence itself is the finding.
| Exposure | Dementia | Parkinson’s | Cancer | Cardiovascular disease |
|---|---|---|---|---|
| Physical inactivity | RR 0.80 (0.77-0.84) protective | RR 0.79 (0.68-0.91) protective | a protective cause | established lever |
| Excess body fat | midlife RR 1.31 (1.02-1.68) | not significant | convincing/probable cause, 12 of 17 cancer sites | established lever |
| Diabetes / high blood sugar | HR 1.24 per 5-yr-earlier onset | RR 1.31 (1.10-1.57) | via body fat | established lever |
| High blood pressure | untreated HR 1.42 (1.15-1.76) | — | — | established lever |
| High LDL | >3 mmol/L HR 1.33 | — | — | established lever |
| Smoking | midlife RR 1.30 (1.18-1.45), harm | RR 0.64 (0.60-0.69), protective — an artifact, not a lever (see below) | a cause | established harm |
| Heavy alcohol use | >21 units/week HR 1.22 (1.01-1.48) | — | a cause | J-shaped; the protective-looking low-dose arm is artifact-suspect |
(Livingston et al., 2024) (Chen et al., 2021) (World Cancer Research Fund & American Institute for Cancer Research, 2018)
Read this table as co-membership evidence, not a shared magnitude. Each column is a different outcome, measured in a different population, over a different follow-up. A row does not mean “this exposure costs everyone the same amount”; it means the same exposure shows up, in the same direction, in disease bodies that were built independently of one another. Whether a given relative risk translates into a large or a small absolute benefit for any one person still depends on that person’s baseline risk for each disease — a question the later sections take up disease by disease.
On alcohol specifically: the harm direction above is the one to act on — past roughly 21 units a week, dementia risk rises, and alcohol is a recognized cause of several cancers with no evidence of a safe floor. The apparent protection at low intake is the textbook case of a U-shaped association that does not survive scrutiny of who ends up in the “non-drinking” comparison group. Former drinkers who quit because they were already getting sick get folded into the reference category, which manufactures a protective-looking dip at low doses -> The U-Shaped Association Artifact. Nothing here should be read as licensing a “safe” drinking amount; the number worth carrying is the harm threshold, not a floor.
This is exactly the situation Layer 1’s ranking logic is built for. Ranking by expected effect size and certainty does not mean ranking one outcome at a time: a lever that moves three diseases outranks one that moves only one, at an equal effect on each -> Layer 1 - Ranking Interventions for a Stratum. Physical activity and the vascular-metabolic cluster (blood pressure, LDL, glycaemia, adiposity, smoking) sit at the top of both the Big Rocks (Elderly) and Big Rocks (Median) rankings for exactly this reason. Not because any single per-disease effect is unusually large — because the same short list keeps paying out across the whole outcome menu at once. The shared core is not a coincidence sitting beside the ranking; once multi-outcome breadth counts toward a lever’s rank, the shared core is the ranking.
Why does the same list keep recurring? The most economical explanation is that these exposures injure a common cardiometabolic-vascular substrate — the blood vessels and the systemic metabolic machinery that dementia, cardiovascular disease and (via body fat and inflammation) some cancers all depend on. That is a candidate mechanism, not an outcome finding. It is consistent with the overlap above but not independently tested here. And it does not crown any single exposure as “the cause” of age-related disease in general: an effect arrives only when a whole set of conditions is present, and ranking by breadth is a statement about where to act, not about what explains the outcome -> Layer 1 - Ranking Interventions for a Stratum.
One exposure in the table already breaks the pattern outright: smoking’s apparent protection against Parkinson’s, flagged above. Later sections return to why Parkinson’s and a few other diseases resist the shared-lever logic more broadly.
Does pulling those levers actually prevent a disease?
The shared list lowers risk markers reliably. Whether it prevents a disease has been tested most directly on dementia, where two bets were run and must be kept apart. A multidomain lifestyle bundle — diet, exercise, cognitive training and vascular monitoring delivered as one unit — has been tested in randomized trials and pooled. It has not been shown to prevent the diagnosis, only to move a cognitive test score in some trials (Ngandu et al., 2015) (Coley et al., 2025). A single cardiometabolic lever — lowering blood pressure — has been tested at scale, and it does prevent incident dementia in a randomized trial: a small but real absolute magnitude, on a pill already prescribed for the heart (Peters et al., 2022). Neither finding overturns the other; they answer different questions — a non-decomposable package versus one well-understood exposure.
This is the shared-lever thesis’s sharpest test, so it earns a full appraisal of its own in Dementia Prevention: the trial base, the responder-subgroup null that closes off targeting the highest-risk person, the per-lever ranking, and the diet and sleep candidates that turn out to route through the same cardiometabolic rocks rather than adding independent targets.
Cancer, heart disease, diabetes — the increments beyond the rocks
Cancer and the cardiometabolic diseases tell the same shared-rock story with fewer surprises — and a shorter list of extras.
Heart disease and diabetes add almost nothing beyond the shared core. Blood pressure, LDL, glycaemia, adiposity, smoking and inactivity carry nearly the whole cardiovascular and type-2-diabetes burden. That ranking is worked out in Big Rocks (Elderly) and Big Rocks (Median) rather than re-derived here. One framing point belongs on this page instead: sizing the lifestyle rock against the drug landscape. A mature, low-harm drug for a single marker — a statin for LDL, an antihypertensive for blood pressure — captures most of the benefit that marker has to give. That shrinks the marginal lifestyle rock for that outcome specifically. It does not shrink the rest: a drug manages a marker, while lifestyle that removes the underlying driver keeps the structural leverage and the other channels a single-target drug does not touch.
Diabetes prevention is where the head-to-head has actually been run. Lifestyle vs Metformin for Diabetes Prevention randomized 3234 adults with prediabetes to placebo, metformin (850 mg twice daily), or an intensive lifestyle program (7% weight-loss target, 150 minutes/week of activity). Over an average 2.8 years, diabetes incidence fell from 11.0 to 7.8 cases per 100 person-years on metformin (a 31% relative reduction, 95% CI 17-43%) and to 4.8 on lifestyle (58%, 48-66%) (Knowler, 2002). Lifestyle beat the drug outright — 39% lower incidence head-to-head — and needed roughly half as many people treated to prevent one case (NNT 6.9 vs 13.9 over three years). Metformin’s benefit varied by stratum in this single trial: the point estimate was near-null at a BMI of 22 to under 30 (3% reduction, CI -36 to 30) and largest at a BMI of 35 or more (53%, 36-65), where it matched lifestyle (51%, 34-63). The test for heterogeneity across BMI strata was significant (P<0.05) (Knowler, 2002), but the within-stratum intervals are wide, and the trialists state: «The study had inadequate power to assess the significance of effects within the subgroups, nor were such tests planned.» (Knowler, 2002), so this is a signal to replicate, not an established modifier; lifestyle worked broadly across every subgroup tested.
Hold the outcome scope honestly, though. Twenty-one years later, the same three arms showed no reduction in hard cardiovascular events from either intervention — metformin HR 1.03 (0.78-1.37), lifestyle HR 1.14 (0.87-1.50), both non-significant (Goldberg et al., 2022). In that cohort, widespread out-of-study statin and antihypertensive use diluted whatever effect either arm still had. Preventing or delaying a diabetes diagnosis is demonstrated; that this converts into fewer heart attacks or a longer life is not shown by this trial, in this population.
Cancer adds genuine disease-specific levers that CVD and T2D do not carry. Physical activity, adiposity and alcohol are already shared levers (see above); cancer’s own increments are about what to eat, and what to eat less of. Body fatness is the largest of them by breadth. WCRF grades it a convincing or probable cause across 12 of the 17 cancer sites in its Continuous Update Project, with IARC independently adding thyroid cancer, multiple myeloma and meningioma (World Cancer Research Fund & American Institute for Cancer Research, 2018).
Against that breadth, red and processed meat are a single-site refinement: processed meat carries a convincing colorectal-cancer association (RR 1.16 per 50 g/day, 95% CI 1.08-1.26), red meat a probable one that is not itself statistically significant when pooled (RR 1.12 per 100 g/day, 1.00-1.25) (World Cancer Research Fund International, 2018). WCRF’s own gram target — up to about 350-500 g cooked red meat a week, very little processed meat — is chosen to balance meat’s micronutrient contribution against that colorectal risk (World Cancer Research Fund & American Institute for Cancer Research, 2018).
NutriRECS re-pooled the same cohort evidence into absolute terms. A realistic 3-servings/week cut buys about 7 fewer cancer deaths per 1000 people over a lifetime — low certainty, and null on eight other cancer outcomes (Johnston et al., 2019). Fibre runs the other way, probably protective for colorectal cancer above roughly 30 g/day -> Dietary Fibre and Health. On WCRF’s own grading scale, meat and fibre are both smaller, more site-specific levers than the adiposity rock beneath them -> Body Fatness and Cancer Risk.
Most of the population’s cancer burden sits entirely outside this diet/activity/adiposity list — tobacco, infection (HPV, hepatitis, H. pylori) and occupational exposure carry a comparable or larger share and fall outside this deliverable’s lifestyle scope.
Keeping the body working — frailty, muscle, bone, falls
For the oldest adults the decisive outcome is often not whether a disease arrives but whether the body keeps working — a different lever set. Length and function stay separate axes here, not one score. An intervention can push back a disease’s arrival, preserve mobility, or do neither; this section keeps the three apart rather than folding them into a single healthspan number.
Frailty is a marker with teeth, and also something you can change. Frailty — reduced physiological reserve across multiple organ systems — predicts a wide set of patient-important outcomes. In Vermeiren’s pooled meta-analysis of 31 studies and 158,764 community-dwelling adults over 65, the frail and prefrail together, versus the robust, carried a raised risk of death (pooled HR/RR 1.83, 95% CI 1.68-1.98), of disability in basic activities of daily living (HR/RR 1.62, 1.50-1.76), and of falls (HR/RR 1.24, 1.12-1.37). Split out, the risk of death was roughly double the robust level in the frail (RR 2.01, 1.82-2.22) and about 1.5 times it in the prefrail (RR 1.47, 1.32-1.62) (Vermeiren et al., 2016). That alone would make frailty only a stratifier.
Racey pooled 26 trials in prefrail and frail older adults, and that closes the gap: physical-activity programs moved mobility (standardized mean difference 0.60), activities of daily living (0.50), and frailty status itself (risk ratio 0.58, moderate certainty) (Racey et al., 2021). Racey raises the concern that activity recommended for the general older adult «may be too advanced or too intense for a frailer population» (Racey et al., 2021); that the dose must come down is a reasonable precaution, not a tested finding. But the direction holds: frailty identifies who has the most to gain, and training moves the thing identified.
Grip strength and muscle mass are cheap numbers that track both function and mortality — measurements, not targets to chase. In UK Biobank (n=502,293), each 5 kg of lower grip strength carried a 16-20% higher hazard of all-cause mortality, adjusted for age, comorbidity, activity and more (Celis-Morales et al., 2018). A later 48-cohort, 3.14-million-adult pooled analysis that folds in UK Biobank put the weakest third of grip at 1.58 times the all-cause mortality of the strongest third (HR 1.58, 1.40-1.78) (López-Bueno et al., 2022).
Low appendicular muscle mass predicts mortality on its own terms too — people who died carried about 0.18 standard deviations less muscle mass than survivors, an association not fully explained by their strength (de Santana et al., 2021). Both measures are substantially heritable and disease-sensitive, so they are markers as much as levers. No trial shows that raising grip strength or muscle mass, on its own, lowers mortality. Measure them to place someone in a risk stratum; the lever behind them is resistance training and protein.
Resistance training drives muscle and strength; protein is a modest, bounded adjunct. Across 49 RCTs, adding protein to resistance training added a further 2.5 kg to one-repetition-maximum strength and 0.3 kg of lean mass on top of what training alone delivered (Morton et al., 2017). The oft-quoted target sits around 1.62 g of protein per kg of total body weight per day, as actually weighed — not lean mass. It is a soft, statistically non-significant knee (95% CI 1.03-2.20, p=0.079), better read as a wide region than a precise point: a floor worth reaching rather than a ceiling to fear, since higher intakes show no harm to healthy kidneys.
In the obese the number is not merely lower — it is undefined until the denominator is named. Total and lean weight diverge roughly twofold, and the trial sample behind it carried no obese stratum at all. That is a gap, not a finding, and it stays a gap for older and energy-restricted adults too -> Protein and Resistance Training for Muscle and Strength. A separate older-adult maintenance target sits lower, around 1.0-1.2 g/kg/day (1.2-1.5 in illness) — a different objective, on a different evidence base -> Protein Intake for Older Adults.
Falls are prevented by balance training, and the effect is unusually solid. A Cochrane review of 108 trials (23,407 participants, mean age 76) found exercise cut the rate of falls by 23% (rate ratio 0.77, 95% CI 0.71-0.83) at HIGH-certainty GRADE (Sherrington et al., 2019). That is a rare thing in this domain: an RCT-based effect on a directly observed, patient-important outcome. But the active ingredient is specifically balance and functional training (rate ratio 0.76, HIGH certainty). Resistance training alone has not been shown to reduce falls (rate ratio 1.14, 0.67-1.97, five small trials, very low certainty — an interval compatible with benefit or harm, so insufficient evidence rather than a null) (Sherrington et al., 2019) — a different mechanism from the muscle and mortality levers above, not a contradiction of them.
Fracture reduction follows downstream, more weakly evidenced (RR 0.73, 0.56-0.95, LOW certainty). Exercise reaches bone through two distinct channels, and this is only the larger one: preventing the fall, not measurably strengthening the bone itself. The bone-loading channel is smaller, but it is no longer surrogate-only: a 2022 meta-analysis of 11 controlled exercise studies shows structured exercise cuts major osteoporotic fractures directly (RR 0.75, 0.54-0.94) (Hoffmann et al., 2022), so loading reaches the outcome a person cares about and not only bone density -> Exercise and Bone Mineral Density. That fracture meta-analysis comes from the same research group as the density one, so the two legs are not independent and the certainty on the loading channel is moderate, not high (inferred from Hoffmann et al., 2022). And once someone is already frail, the fall effect is not established: the frail-and-prefrail pooling above found no significant fall reduction (RR 0.80, 0.51-1.26, very low certainty) even while mobility and frailty status still improved (Racey et al., 2021). That interval is wide enough to include the reduction seen in the general older population (rate ratio 0.77, a differently defined falls measure), so the effect is unproven in the frail, not shown absent. Balance training carries its high-certainty evidence for the older adult who is not yet frail; in the already-frail it is a reasonable bet on thinner evidence.
Where the incidence lever inverts: weight loss helps the disease list and can harm the frail. Losing weight is a genuine lever against cancer and cardiometabolic incidence (above) and against knee osteoarthritis symptoms and joint load. But unintentional weight loss is itself one of the criteria that defines frailty in the Fried phenotype. Deliberate weight loss can harm a frail older adult by accelerating the loss of muscle and reserve it is meant to protect. The same exposure that lowers risk in an overweight, disease-incidence stratum becomes a route-(c) contraindication in the frail elderly. The sign inverts by stratum: a recommendation built for the middle-aged should not be carried over to the oldest-old without checking which stratum it is being applied to -> Shared Modifiable Levers Across Age-Related Diseases.
The shared-lever logic is powerful but not universal — two places break it, and the breaks are instructive.
Where the shared logic breaks — Parkinson’s and the eyes
Two corners of this deliverable follow the shared-lever pattern only partly, or not at all, and both are worth stating precisely rather than folding into the general case.
Parkinson’s is the sharper break. Chen’s 2021 umbrella review pooled 46 systematic reviews across six categories and more than 80 factors, and it grades its own evidence base bluntly. Under AMSTAR-2, none of the 46 rated high or moderate quality: «Seven SRs (15.2%) were judged to be of low methodological quality, while the remaining 39 (84.8%) were judged to be of critically low quality» (Chen et al., 2021). Of 50 statistically significant associations found, only 19 survived to prospective (cohort) evidence. The remaining 31 rest on case-control or mixed designs, more prone to recall and selection bias. That ceiling governs every number below.
Physical activity is the one shared lever that clearly holds: RR 0.79 (95% CI 0.68-0.91, 8 cohort/ nested-case-control studies, I2=0) (Chen et al., 2021), strongest in men (RR 0.68) and at moderate-to-vigorous intensity (RR 0.71), null in women (RR 0.91, 95% CI 0.72-1.14). This figure traces, inside Chen’s umbrella, to Fang et al. 2018’s own meta-analysis of physical activity and PD — a source the fabric does not separately hold. That is a named gap, not an oversight. Without the Fang MA itself, the Parkinson’s activity signal holds only at the direction and magnitude Chen reports, and no Parkinson’s-specific dose-response, population-attributable fraction, or absolute-risk figure can be built on top of it.
Diabetes is the other shared lever that holds, modestly: RR 1.31 (95% CI 1.10-1.57, 4 cohort studies) «diabetes significantly increased the risk of PD» (Chen et al., 2021). But three of the cardiometabolic rocks that anchor the shared-core case elsewhere in this deliverable were assessed here and came back non-significant: adiposity — «no significant associations were found between PD development and BMI or serum cholesterol» (Chen et al., 2021) (BMI per 5 kg/m2, RR 1.00, 95% CI 0.89-1.12); blood pressure — «no significant association was found between hypertension and PD (pooled RR: 0.98, 95% CI: 0.82 to 1.17, … 2 cohort studies)» (Chen et al., 2021); and lipids — LDL-C found no significant association either (RR 0.58, 95% CI 0.31-1.07, wide interval, 3 studies).
Pulling the shared rocks therefore does far less for Parkinson’s than for dementia, cancer or heart disease. And it works through a narrower channel — physical activity and, modestly, glycaemic control, not the full cardiometabolic set.
The direction flips outright on smoking and coffee, and the flip is the instructive part. Smoking’s association with lower PD risk (RR 0.64, 95% CI 0.60-0.69) and coffee’s (RR 0.67) and caffeine’s (RR 0.55) are PD’s strongest apparent protective signals — running opposite to every other disease in this deliverable. The review attributes them to reverse causation over Parkinson’s years-to-decades prodrome. Early, undiagnosed PD lowers activity, smoking and coffee intake before diagnosis, which a cohort design cannot fully rule out.
Chen’s own reading of the smoking arm is explicit that it changes nothing about smoking policy: «its protective effect for PD development does not impact public health strategies for reducing smoking» (Chen et al., 2021). This is the one place in the whole deliverable where the shared-lever logic would license a genuinely harmful action — smoke to protect the brain. And it is exactly where the signal is an artifact, the case The U-Shaped Association Artifact exists to catch.
The eyes show a milder version of the same lesson: a lever proven for one organ does not automatically transfer to its neighbour. Aune’s 2026 SR-MA of prospective cohorts reaches WCRF probable causality for physical activity and cataract — RR 0.90 (95% CI 0.86-0.94, 10 cohorts, ~1.9 million participants). But for age-related macular degeneration the same paper finds the evidence «limited, and no conclusion could be drawn»: RR 0.92 (95% CI 0.84-1.01), an interval crossing 1 (Aune et al., 2026).
The authors state the contrast directly: «This meta-analysis provides further support for an inverse association between physical activity and risk of cataract, but an association with age-related macular degeneration was less evident» (Aune et al., 2026). The AMD result is insufficient evidence, not a demonstrated null: the wide interval and thin dose-response data (3 cohorts) cannot exclude a real small effect. But physical activity is not (yet) a proven AMD-specific lever the way it is for cataract.
What does reach AMD is the familiar vascular set, and it adds nothing new to the ranking. Babaker’s 2025 SR-MA of 18 observational studies (~44,440 participants) finds smoking (OR 1.86, 95% CI 1.33-2.6), hypertension (OR 1.24, 1.09-1.4), cardiovascular disease (OR 1.44, 1.11-1.87) and diabetes (OR 1.44, 1.3-1.6) all significantly associated with late AMD, while BMI, cerebrovascular disease and blood lipids were not (Babaker et al., 2025). These are prognostic (route-a) associations, not intervention effects. They are the same big rocks already ranked on mortality and cardiometabolic grounds — AMD is one more organ carrying the cost of the dominant exposures, smoking above all, not a fresh lever.
A Mediterranean-diet pattern shows a separate, somewhat better-evidenced signal for AMD progression specifically (prospective cohort pool: HR 0.77, 95% CI 0.67-0.88) (Marques-Couto et al., 2025). But MedDiet is already a big rock on cardiometabolic grounds, so for someone who would adopt the pattern anyway this is confirmatory, not additive.
The lesson both exceptions teach is the same one: “shared” in this deliverable means shared for the diseases and levers it has actually been shown to hold for, never a default assumption. Parkinson’s is a disease where most of the shared core does not transfer. The eyes show that even within one organ system, one lever (physical activity) can transfer to one disease (cataract) and not its neighbour (macular degeneration).
Length, trajectory, and how the ranking shifts by age
The wiki holds no single scalar for “health,” so a lever’s payoff has to be named by which axis it moves: length of life, or the shape of the years before death — function, independence, freedom from pain and cognitive decline. These are not the same currency and should not be collapsed into one number.
Dementia is where this distinction bites hardest. Delaying dementia onset only compresses the years lived with the disease if onset moves back further than life expectancy extends — the compressed-morbidity outcome this deliverable’s outcome menu names. This is a plausible entailment of “pull the levers earlier and keep them low longer,” not a measured finding . None of the trials held here — Peters’ BP-lowering IPD meta-analysis, the FINGER/MAPT/preDIVA/Coley bundle — report a shift in age-at-onset or years-of-dementia-free-life. They report whether dementia was diagnosed by the end of follow-up, an event count, not a trajectory.
Livingston’s Commission states the timing rule plainly — «decrease risk factor levels early (the earlier, the better) and keep them low throughout life (the longer, the better)», and «it is never too early or too late to reduce» dementia risk (Livingston et al., 2024). But that is a policy recommendation, not a measurement of the trajectory it implies.
The gap runs through the function axis generally. The one SR the fabric holds that tries to measure a composite functional trajectory directly (intrinsic capacity plus quality of life) flags that its own outcome measures are the ones this field measures worst — self-reported, unblindable, Hawthorne-prone. So a positive reading is discounted, not taken at face value Intrinsic Capacity and Multidimensional Healthspan. Naming this gap is itself the decision-relevant move: a clean incidence result should not be read as though it had settled a trajectory question it never asked.
The ranking of levers is not static across age, and the reason is arithmetic more than biology. A 10-year risk window understates the case for acting in a 30- or 40-year-old with an unfavourable but modest risk-factor profile. A decade captures only the first slice of decades of compounding exposure. ESC states this for cardiovascular risk directly: «The 10-year CVD risk in relatively young, apparently healthy people is on average low, even in the presence of high risk factor levels, but the lifetime CVD risk is in these circumstances very high» (European Society of Cardiology, 2021). The logic transports to dementia and the other diseases in this deliverable. Midlife exposure to the shared core (LDL, blood pressure, obesity, smoking, diabetes) drives late-life incidence across diseases, so a young adult’s low 10-year single-disease number understates a lever that pays into several late-life outcomes at once.
The apparatus does not transport. ESC’s LIFE-CVD model and its CVD-free-years currency are calibrated for cardiovascular disease only, and the fabric holds no equivalent lifetime model for dementia or Parkinson’s. So “act early” is warranted qualitatively here, but no cross-disease lifetime-years figure can be quoted . ESC also bounds its own frame: below 40, «CVD risk predictions, as well as predictions of lifetime benefit of risk factor treatment, are likely to be imprecise». Drug treatment is not usually considered at that age — lifestyle carries the weight instead (European Society of Cardiology, 2021).
At the other end of life the ranking shifts again, mostly toward function. In a lean, physically active, non-smoking elderly person the cardiometabolic big rocks are already largely pulled, so the marginal levers move toward resistance training and adequate protein, balance-and-strength work against falls, and frailty status itself — covered in full above and in Big Rocks (Elderly). Baseline risk does real work here without needing any subgroup claim: the same relative effect buys more absolute benefit in a higher-baseline-risk stratum. That is part of why lowering blood pressure prevents incident dementia in absolute terms that are small in a trial population enrolled at modest baseline risk, yet would plausibly buy more starting from a higher one. Meanwhile a multidomain programme layered on an unselected older population already receiving good vascular care found no reduction at all — a route-(a) point in miniature, a lever with little absolute room left to work whatever the relative logic says. Both results, with their trial numbers and headroom reading, are worked in Dementia Prevention -> Baseline Risk and the Relative-Absolute Split.
One structural limit closes the ranking question. The 14-factor dementia population-attributable-
fraction map, WCRF’s preventable-fraction estimates, and every other PAF-style figure in this
deliverable are population quantities, not per-person ones. The individual factors’ PAFs overlap
and therefore do not sum. Removing a modifiable exposure does not remove that share of one person’s own
risk, and no single aggregate cross-disease burden figure can be built by adding PAFs across the
diseases covered here — a structural limit (G, needs aggregation the fabric cannot perform), named
rather than computed.
What does not move the needle much
That leaves the exposures people spend the most attention on — and where attention runs inverse to effect. A confirmed small effect is as reportable a result as a confirmed large one, so an honest map of this territory is neither “everything checks out” nor “nothing here matters.” Dementia is where these small levers have been mapped most exhaustively, and the mapping is consistent. Ultra-processed food, fruit and vegetables, flavonoids, fish-oil capsules, sleep, mind-body exercise and air pollution each carry at most a small, low-certainty signal. Where one survives scrutiny at all, it runs through the cardiometabolic rocks already counted rather than sitting beside them as a fresh target. The per-lever appraisal — the numbers, the reverse-causation and measurement-error checks, and the diet-versus-pill split — lives in Dementia Prevention.
Three things the evidence cannot yet tell us.
What the evidence still cannot tell us
Parkinson’s disease has a physical-activity signal, but not yet a sized one. The activity association for Parkinson’s rests on a 2021 umbrella review of the field rather than a purpose-built dose-response meta-analysis (the derivation is in the Parkinson’s section above) (Chen et al., 2021). The direction and reported magnitude hold. A Parkinson’s-specific dose target, absolute-risk figure, or population-attributable fraction cannot be built from evidence never designed to supply one.
The biology that might explain why one lever touches several diseases at once is not evidence this fabric holds. The pattern itself — that the same handful of exposures recurs across dementia, cardiovascular disease, cancer and physical function — is well established across the disease-specific sources above. The aging-biology literature that would explain that pattern mechanistically is absent — cellular senescence, chronic inflammation, and related mechanisms sometimes grouped as “the hallmarks of aging”. Treat any claim about why the levers overlap at that biological level as unstated, not as a confirmed backbone underneath the pattern. The overlap remains actionable without it.
How much total benefit one lever buys, added up across every disease it touches, cannot be computed from what is held here. Each disease’s effect estimate for a given lever comes from a different population, follow-up length and outcome definition. Summing or averaging them across dementia, cancer, heart disease and falls would manufacture a combined number no study measured. That is a structural limit on what a review of separate studies can produce, not a gap a bigger meta-analysis eventually closes. Closing it would need a single study designed to track the combined outcome directly, and none exists.
What to do
Most people chasing better odds against dementia, cancer and heart disease do not need a different diet or routine for each disease. A short, shared list of changes lowers the risk of several of them at once: stop smoking, keep blood pressure and cholesterol down, manage blood sugar, carry less body fat, stay physically active, and drink less alcohol. Staying active is the single most useful item on that list. It is the one lever that also keeps the body working day to day — muscle, bone, balance — not only diseases at bay over decades. Nothing sold as a substitute matches it.
For most of these levers the individual payoff is modest. And most of the evidence behind them is observational rather than proof from a trial that changing the behavior changes the disease. The clearest exception is blood pressure: lowering it in a randomized trial reduced the number of people who went on to develop dementia. The benefit to any one person was small, but it was real, and it arrived as a bonus on a treatment already worth doing for the heart — not from a separate brain-health regimen.
The reverse bet has not paid off. A packaged program of brain games, diet coaching and supplements, sold specifically to prevent dementia, can move a cognitive test score in some people. But it has not been shown to keep people from developing the disease — including when the program targets people already at higher risk.
The details many people spend the most energy on — cutting packaged food, adding more fruit and vegetables, chasing flavonoid-rich foods or fish-oil pills, fixing sleep — mostly work, to the extent they work at all, by nudging the same handful of levers already listed, not by adding a new one. They are worth doing as part of a generally sound diet and routine. They are not worth optimizing on their own for brain health.
The ranking shifts with age. A younger adult with low near-term risk still benefits from acting early. Several of these diseases develop over decades, and the levers that prevent them work best pulled sooner rather than later. Older adults gain the most from a different set — resistance exercise, adequate protein, and balance training that protect muscle, bone and the ability to avoid a fall. One caution runs the other way: losing weight helps prevent several of these diseases in someone carrying excess fat, but it can harm an already-frail older adult, so it is not a universal recommendation late in life.
None of this adds up to a single number worth optimizing. It adds up to a short list, pulled in the right order, and adjusted as a person ages.
Evidence box
Question ’For an adult deciding how to lower their risk of the diseases of ageing — cardiovascular disease, cancer, dementia, Parkinson”s, frailty/sarcopenia, osteoporosis: which modifiable exposures move which disease, how much, how certainly, do the diseases share a common core of levers or need separate regimens, and how does the ranking shift by age stratum?‘ Evidence included 22 sources — 14 gold, 8 high Overall certainty Medium (see Rating Certainty of Evidence) Source-selection note All sources are gold or high tier. Last updated 2026-10-02 · Independently reviewed: No · Full edit history